Brief: Mustang Bio Inc Says U.S. FDA Has Granted Orphan Drug Designation To MB-106
22/06/2022 14:23
June 22 (Reuters) - Mustang Bio Inc MBIO.O :
* MUSTANG BIO INC - U.S. FDA HAS GRANTED ORPHAN DRUG
DESIGNATION
TO MB-106
Source text for Eikon: ID:nGNX8xLR06
Further company coverage: MBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie